Adage Capital Partners GP L.L.C. Increases Stake in Danaher Corporation $DHR

Adage Capital Partners GP L.L.C. increased its stake in Danaher Corporation (NYSE:DHR) by 2.2% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,002,895 shares of the conglomerate’s stock after purchasing an additional 21,469 shares during the period. Adage Capital Partners GP L.L.C. owned 0.14% of Danaher worth $198,112,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also bought and sold shares of DHR. White Pine Capital LLC grew its holdings in shares of Danaher by 1.4% during the second quarter. White Pine Capital LLC now owns 3,494 shares of the conglomerate’s stock valued at $690,000 after buying an additional 49 shares during the last quarter. Boyd Watterson Asset Management LLC OH lifted its position in Danaher by 2.1% during the 2nd quarter. Boyd Watterson Asset Management LLC OH now owns 2,524 shares of the conglomerate’s stock worth $499,000 after acquiring an additional 51 shares during the period. Worth Financial Advisory Group LLC grew its stake in Danaher by 4.6% during the 2nd quarter. Worth Financial Advisory Group LLC now owns 1,195 shares of the conglomerate’s stock valued at $236,000 after purchasing an additional 53 shares during the last quarter. Bruce G. Allen Investments LLC increased its holdings in shares of Danaher by 13.1% in the second quarter. Bruce G. Allen Investments LLC now owns 467 shares of the conglomerate’s stock valued at $92,000 after purchasing an additional 54 shares during the period. Finally, Texas Bank & Trust Co increased its holdings in shares of Danaher by 1.6% in the second quarter. Texas Bank & Trust Co now owns 3,567 shares of the conglomerate’s stock valued at $705,000 after purchasing an additional 55 shares during the period. Institutional investors and hedge funds own 79.05% of the company’s stock.

Insider Activity at Danaher

In other news, SVP Brian W. Ellis sold 21,776 shares of the business’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $219.23, for a total value of $4,773,952.48. Following the completion of the sale, the senior vice president directly owned 14,553 shares in the company, valued at $3,190,454.19. The trade was a 59.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Georgeann Couchara sold 5,174 shares of the company’s stock in a transaction that occurred on Monday, November 10th. The stock was sold at an average price of $210.42, for a total value of $1,088,713.08. Following the transaction, the senior vice president directly owned 2,625 shares of the company’s stock, valued at approximately $552,352.50. The trade was a 66.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 30,248 shares of company stock worth $6,609,663 in the last 90 days. Corporate insiders own 11.10% of the company’s stock.

Analyst Ratings Changes

DHR has been the subject of a number of research reports. Royal Bank Of Canada set a $241.00 target price on Danaher in a report on Tuesday, September 2nd. Rothschild & Co Redburn reissued a “neutral” rating and set a $220.00 price target (down from $245.00) on shares of Danaher in a research report on Wednesday, October 8th. Bank of America decreased their price objective on shares of Danaher from $230.00 to $220.00 and set a “buy” rating for the company in a research note on Monday, September 22nd. Morgan Stanley began coverage on shares of Danaher in a research note on Monday, December 1st. They issued an “overweight” rating and a $270.00 price objective on the stock. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Danaher in a report on Wednesday, October 8th. Twenty-one investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $246.79.

Danaher Price Performance

NYSE:DHR opened at $226.70 on Friday. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.52 and a quick ratio of 1.10. The company has a 50 day moving average price of $218.51 and a 200-day moving average price of $205.67. Danaher Corporation has a 1-year low of $171.00 and a 1-year high of $258.23. The firm has a market cap of $160.13 billion, a price-to-earnings ratio of 46.74, a price-to-earnings-growth ratio of 4.51 and a beta of 0.89.

Danaher (NYSE:DHR) last released its quarterly earnings results on Monday, October 20th. The conglomerate reported $1.89 EPS for the quarter, beating the consensus estimate of $1.72 by $0.17. Danaher had a net margin of 14.44% and a return on equity of 10.92%. The company had revenue of $6.05 billion for the quarter, compared to analyst estimates of $6 billion. During the same quarter last year, the business earned $1.71 earnings per share. The firm’s revenue was up 4.4% on a year-over-year basis. Equities research analysts forecast that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 30th. Stockholders of record on Friday, December 26th will be given a dividend of $0.32 per share. The ex-dividend date is Friday, December 26th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. Danaher’s dividend payout ratio (DPR) is 26.39%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.